Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports
Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports
The Life Sciences Report
Menu
Articles
Biotechnology / Pharmaceuticals
Cannabis
Healthcare Services
Life Sciences Tools & Diagnostics
Medical Devices
Nutraceuticals
Psychedelics
Disclosures
Featured news in
The Life Sciences Report
DURECT Corp.
(DRRX:NASDAQ)
DURECT Announces Closing of Public Offering of Common Stock (4/29/2016)
view
RepliCel Life Sciences Inc.
(RP:TSX.V; REPCF:OTCQB)
RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price (4/29/2016)
view
DURECT Corp.
(DRRX:NASDAQ)
DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference Call (4/28/2016)
view
Celgene Corp.
(CELG:NASDAQ)
Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View (4/29/2016)
view
Celgene Corp.
(CELG:NASDAQ)
Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook (4/28/2016)
view
MiMedx Group Inc.
(MDXG:NASDAQ)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference (4/28/2016)
view
Caladrius Biosciences Inc.
(CLBS:NASDAQ)
Caladrius Biosciences to Host 2016 First Quarter Financial Results Conference Call on May 5 at 5:00 pm Eastern Time (4/28/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
StockNewsNow.com Publishes Q3 2015 Review SNNLive Video Interview With Immune Pharmaceuticals, Inc. (11/2/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid (11/9/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Provide Corporate Update on November 12, 2015 (11/5/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces Third Quarter 2015 Corporate Update, Financial Results and Conference Call Details (11/12/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology (12/28/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces Enrollment of the First Patient into the Phase 2 Clinical Trial with Bertilimumab in Ulcerative Colitis (11/17/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development (12/7/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody (12/14/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology (1/4/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Expands Leadership Team (11/19/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals CEO Updates Shareholders On Company Progress (12/9/2015)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan (1/12/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals to Present at 18th Annual BIO CEO & Investors Conference (2/8/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues (2/24/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals and The International Pemphigus & Pemphigoid Foundation (IPPF) Celebrate Rare Disease Day (2/29/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology (3/22/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Names John Neczesny to its Board of Directors (2/3/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors (2/10/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors (2/25/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting (3/17/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results (3/30/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age (4/19/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report (4/28/2016)
view
Immune Pharmaceuticals Inc.
(IMNP:NASDAQ)
IMMUNE PHARMS INC reaches new 52-Week Low (4/22/2016)
view
Relmada Therapeutics Inc.
(RLMD:NASDAQ)
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference (4/28/2016)
view
Celgene Corp.
(CELG:NASDAQ)
Will Vertex (VRTX) Stock Decline on 1Q Earnings Miss? (4/28/2016)
view
Celgene Corp.
(CELG:NASDAQ)
Celgene (CELG) Beats on Q1 Earnings, Misses on Revenues (4/28/2016)
view
Celgene Corp.
(CELG:NASDAQ)
AbbVie (ABBV) Beats on 1Q Earnings, Lowers View on Deal (4/28/2016)
view
Sunesis Pharmaceuticals Inc.
(SNSS:NASDAQ)
Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights (4/28/2016)
view